Amgen has announced that the European Commission has approved the use of Imlygic (talimogene laherparepvec) for the treatment of adults...
Amgen has announced detailed results from a pivotal Phase III trial evaluating talimogene laherparepvec in patients with unresected stage IIIB,...
Amgen has announced top-line results from the Phase III trial in Melanoma, which evaluated the efficacy and safety of talimogene...
A joint FDA Advisory Panel (Cellular,Tissue and Gene Therapy and Oncologic Drugs ) has voted to recommend approval to T-Vec...
Amgen has announced the publication of primary results from the Phase III OPTiM study in the Journal of Clinical Oncology...
Amgen has announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized...
Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines...
Amgen has announced that the FDA has approved the Biologics License Application for Imlygic (talimogene laherparepvec), a genetically modified oncolytic...
Amgen has announced interim overall survival (OS) results from a pivotal Phase III trial evaluating talimogene laherparepvec in patients with...
Amgen has announced that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory Committee (ODAC)...